MIL-OSI Europe: Written question – Specific action by the EU to ensure the security of supply of critical medicines – E-001492/2025

Question for written answer  E-001492/2025
to the Commission
Rule 144
Gerald Hauser (PfE)

The increasing dependence of EU Member States on third countries – particularly China and India – for their supply of medicines is undoubtedly one of the biggest problems facing the health-care sector. Currently, around 80% of all active pharmaceutical ingredients come from these two countries. This is considered one of the main reasons for the growing number of supply shortages of medicines.

The Critical Medicines Alliance, set up in January 2024, is a consultative body tasked with proposing how to secure the EU’s of supply of critical medicines, supporting efforts to effectively prevent and resolve shortages.

• 1.What specific measures does the Commission intend to take to ensure that critical medicines and their raw materials are once again produced in sufficient quantities in the EU and that supply chains are truly diversified?
• 2.What specific measures does the Commission intend to take to shield patients from the foreseeable price rises in critical medicines as a result of increased production in the EU and the diversification of supply chains?

Submitted: 10.4.2025